Innoviva Gets FDA Approval for Gonorrhea Drug

Dow Jones

2025/12/13

By Katherine Hamilton

Innoviva received approval from the Food and Drug Administration for Nuzolvence, a treatment of gonorrhea.

Nuzolvence has been approved as a single-dose oral medication to treat uncomplicated urogenital gonorrhea in patients 12 years and older, the biopharmaceutical company said Friday.

Innoviva plans to commercialize the drug in the second half of 2026, either in collaboration with a commercialization partner or independently.

The approval comes after Nuzolvence demonstrated non-inferiority compared with other treatments in a phase 3 trial of 930 patients.

Gonorrhea is the second-most common sexually transmitted bacterial infection in the world, with more than 82 million new cases a year, according to the company. Without timely treatment, it can lead to serious and potentially permanent health complications.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

December 12, 2025 17:14 ET (22:14 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2591684101"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2591684101\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2591684101?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-13 06:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591684101","market":"other","top_or_hot":-1,"title":"Innoviva Gets FDA Approval for Gonorrhea Drug","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Innoviva received approval from the Food and Drug Administration for Nuzolvence, a treatment of gonorrhea. \n</p>\n<p>\n  Nuzolvence has been approved as a single-dose oral medication to treat uncomplicated urogenital gonorrhea in patients 12 years and older, the biopharmaceutical company said Friday. \n</p>\n<p>\n  Innoviva plans to commercialize the drug in the second half of 2026, either in collaboration with a commercialization partner or independently. \n</p>\n<p>\n  The approval comes after Nuzolvence demonstrated non-inferiority compared with other treatments in a phase 3 trial of 930 patients. \n</p>\n<p>\n  Gonorrhea is the second-most common sexually transmitted bacterial infection in the world, with more than 82 million new cases a year, according to the company. Without timely treatment, it can lead to serious and potentially permanent health complications. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 12, 2025 17:14 ET (22:14 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innoviva Gets FDA Approval for Gonorrhea Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnoviva Gets FDA Approval for Gonorrhea Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-13 06:14</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Innoviva received approval from the Food and Drug Administration for Nuzolvence, a treatment of gonorrhea. \n</p>\n<p>\n  Nuzolvence has been approved as a single-dose oral medication to treat uncomplicated urogenital gonorrhea in patients 12 years and older, the biopharmaceutical company said Friday. \n</p>\n<p>\n  Innoviva plans to commercialize the drug in the second half of 2026, either in collaboration with a commercialization partner or independently. \n</p>\n<p>\n  The approval comes after Nuzolvence demonstrated non-inferiority compared with other treatments in a phase 3 trial of 930 patients. \n</p>\n<p>\n  Gonorrhea is the second-most common sexually transmitted bacterial infection in the world, with more than 82 million new cases a year, according to the company. Without timely treatment, it can lead to serious and potentially permanent health complications. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 12, 2025 17:14 ET (22:14 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INVA","symbol_name":"Innoviva, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2591684101","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591684101","pubTimestamp":1765577640,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Innoviva received approval from the Food and Drug Administration for Nuzolvence, a treatment of gonorrhea.Nuzolvence has been approved as a single-dose oral medication to treat uncomplicated urogenital gonorrhea in patients 12 years and older, the biopharmaceutical company said Friday.Innoviva plans to commercialize the drug in the second half of 2026, either in collaboration with a commercialization partner or independently.The approval comes after Nuzolvence demonstrated non-inferiority compared with other treatments in a phase 3 trial of 930 patients.Gonorrhea is the second-most common sexually transmitted bacterial infection in the world, with more than 82 million new cases a year, according to the company. Without timely treatment, it can lead to serious and potentially permanent health complications.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INVA":"Innoviva, Inc.","BK4007":"制药"},"translate_title":"Innoviva淋病药物获得FDA批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INVA":1.5},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Innoviva received approval from the Food and Drug Administration for Nuzolvence, a treatment of gonorrhea. \n\n\n  Nuzolvence has been approved as a single-dose oral medication to treat uncomplicated urogenital gonorrhea in patients 12 years and older, the biopharmaceutical company said Friday. \n\n\n  Innoviva plans to commercialize the drug in the second half of 2026, either in collaboration with a commercialization partner or independently. \n\n\n  The approval comes after Nuzolvence demonstrated non-inferiority compared with other treatments in a phase 3 trial of 930 patients. \n\n\n  Gonorrhea is the second-most common sexually transmitted bacterial infection in the world, with more than 82 million new cases a year, according to the company. Without timely treatment, it can lead to serious and potentially permanent health complications. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n  (END) Dow Jones Newswires\n\n\n  December 12, 2025 17:14 ET (22:14 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}